Revolutionizing orthopedic care

Revolutionizing orthopedic care

Enterprising engineers commercialize a sophisticated arthroscopic probe they helped develop as doctoral students at École Polytechnique de Montréal
July 2, 2013

One in 10 Canadians suffers from osteoarthritis, the most common form of arthritis ― a disease that costs more than $4 billion a year in health-care expenses and lost productivity. A portable arthroscopic probe developed by two visionary biomedical engineers while they were still doctoral students at École Polytechnique de Montréal will help detect the early signs of the disease, which is now often diagnosed in later stages. It will also transform how orthopedic surgeons assess cartilage damage in joints.

In 2009, Martin Garon and Éric Quenneville bought the patents for the medical device, called Arthro-BST™, and founded Biomomentum, a company based in Laval, Que. They obtained regulatory approvals from Canada and the European Union in early 2012 for the probe, which is set to hit international markets later this year.

The young company’s potential for growth is considerable, given that problems associated with bones and joints are estimated to increase by more than 125 percent over the next three decades. The worldwide market value of Arthro-BST™ is projected to be about $230 million annually.